Huntington’s disease
is a progressive neurodegenerative disorder that can be inherited from one
generation to another as an autosomal dominant trait. It arises due to
genetically programmed degeneration of neurons in some parts of the brain such
as basal ganglia and cerebral cortex. Basal ganglia plays an important role in
coordinating movement while cerebral cortex regulates perception, thought, and
memory. Degeneration of neurons leads to progressive cognitive impairment and
dementia. People with Huntington’s disease often develop chorea that causes
involuntary muscle movements of hands, face, trunk, and feet. The behavioural
disorders associated with the disease include depression, psychosis, and
changes in personality. Other symptoms of the disease include speech
impairment, anxiety, stress, and difficulty in swallowing. People suffering
from Huntington’s disease usually develop symptoms in their mid-30s and 40s.
However, in few cases, disease symptoms appear in childhood or teens. The
former case represents the adult-onset form of the disease, while the latter is
the early-onset form. The early-onset form is associated with symptoms such as
tremors, slow movements, and rigidity. Children with early-onset disease rarely
live to adulthood. Currently, there is no approved treatment for Huntington’s
disease.
Analysts forecast
the Global Huntington’s
Disease Therapeutics market to
grow at a CAGR of 29.46 percent over the period 2013-2018.
The report
recognizes the following companies as the key players in the Global
Huntington's Disease Therapeutics Market: H. Lundbeck A/S and Valeant
Pharmaceuticals International Inc.
Other Prominent
Vendors in the market are: Auspex Pharmaceuticals, GlaxoSmithKline, Ipsen,
Omeros, Palobiofarma, Pfizer, Prana Biotechnology, Raptor Pharmaceutical, Siena
Biotech, SOM Biotech and Teva Pharmaceutical Industries.
One key trend
emerging in this market is the targeting of novel mechanisms by pipeline
molecules. Drugs with novel mechanisms might prove to be better treatment
options and might affect the course of the disease through their
neuroprotective effects.
Get discount on the
Report @ http://www.sandlerresearch.org/discount?rname=25867
.
Covered in this Report
This report covers
the present scenario and the growth prospects of the Global Huntington’s
Disease Therapeutics market for the period 2014-2018. To calculate the market
size, the report considers the revenue generated through the sales of drugs
approved for the treatment of symptoms of Huntington’s disease.
Global Huntington’s
Disease Therapeutics Market 2014-2018, has been prepared based on an in-depth
market analysis with inputs from industry experts. The report covers the
Americas and the EMEA and APAC regions; it also covers the Global Huntington’s
Disease Therapeutics market landscape and its growth prospects in the coming
years. The report also includes a discussion of the key vendors operating in
this market.
According to the
report, one of the major drivers of the market is the unmet medical needs such
as the lack of safe, efficacious, and disease-modifying treatments with regard
to the treatment of Huntington's disease. Any drug that can cater to these
needs is expected to drive the market during the forecast period.
Further, the report
states that the poor diagnosis rate is one of the major challenges in this
market. This delays the initiation of therapy and affects the quality of life
of the patient.
Single User License
of the Report is Available at USD 2500, Buy the Report @ http://www.sandlerresearch.org/purchase?rname=25867
.
